Opinion|Videos|February 5, 2025
Strategies of Dose Modifications of Osimertinib and Other EGFR Inhibitors
Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including preventive measures and comparisons to managing GI issues from other EGFR inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you handle gastrointestinal side effects in patients taking osimertinib?
- Do you provide any preventive measures for patients, and how does this compare to managing GI issues from other EGFR inhibitors?
Advertisement
Related to this article
Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.
Lisa Carter-Bawa, PhD, MPH, APRN, explains how nurses can counter lung cancer fatalism by pairing honesty with hope and using teach-back.
Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Amivantamab for Recurrent or Metastatic HNSCC
2
Honesty, Hope, and Teach-Back: Lung Cancer Communication for Nurses
3
Teaching Communication as a Clinical Skill for Breast Cancer Care
4
For Young Women With Cancer, Fertility Choices Evolve Beyond Diagnosis
5